Quarterly report pursuant to Section 13 or 15(d)

Other Income / (Expense) (Tables)

Other Income / (Expense) (Tables)

9 Months Ended

Mar. 31, 2024

Schedule of the components of other income (expense)

The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands):


	Quarter Ended					Nine Months Ended
	March 31,					March 31,
	2024		2023		2024		2023
Interest expense	$	(4,005)	$	(1,367)	$	(13,227)	$	(7,513)
Interest income		712		974		2,418		2,375
Gain (loss) on investment⁽¹⁾		—		314		283		50,009
Gain (loss) on equity method investment		(1,747)		—		(5,950)		—
Other non-operating income (expense), net		(874)		64		(359)		1,053
Total other income (expense)	$	(5,914)	$	(15)	$	(16,835)	$	45,924

⁽¹⁾Primarily due to a $0.3 million gain on the sale of our exchange traded investment grade bond funds during the nine months ended March 31, 2024 compared to a $37.2 million gain on the sale of our ChemoCentryx investment and a $11.7 million gain on the sale of Eminence in the nine months ended March 31, 2023.